Tools for Practice Outils pour la pratique


#73 Novel Oral Anti-coagulants (NOACs): is newer better?


CLINICAL QUESTION
QUESTION CLINIQUE
For patients with non-valvular atrial fibrillation (AF), do the NOACs (dabigatran, rivaroxaban, apixaban) have advantages over warfarin?


BOTTOM LINE
RÉSULTAT FINAL
Compared to warfarin, NOACs offer some benefits for patients with non-valvular atrial fibrillation. The decision to use a NOAC or warfarin should be made after reviewing the patient’s previous INR stability, kidney function and discussing the potential benefits and risks, direct and indirect costs with the patient.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
All randomized controlled trials compared NOACs to warfarin: patients mean age 70-73 years, 35-40% female, 1.8-2 years follow-up. All outcomes versus warfarin:
  • Dabigatran: 150mg BID or 110mg BID,1,2 18, 113 patients, mean CHADS2=2.1.
    • Stroke & systemic embolism:
      • 150mg: 0.60% less/year, Number Needed to Treat (NNT)=167.
      • 110 mg: No statistical difference.
    • Major Bleed:
      • 150mg: No statistical difference.
      • 110mg: 0.70% less/year, NNT=143.
    • o Mortality:
      • 150mg: Borderline significance [p=0.051, absolute difference would be 0.49% less/year, NNT=205].
      • 110mg: No statistical difference.
  • • Rivaroxaban: 20mg QD,3 14,264 patients, mean CHADS2=3.5.
    • Stroke & systemic embolism, major bleed, or mortality: No statistical difference.
  • • Apixaban: 5mg BID,4 18,201 patients, mean CHADS2=2.1
    • Stroke & systemic embolism: 0.33% less/year, NNT=303.
    • Major Bleed: 0.96% less/year, NNT=104.
    • Mortality: 0.42% less/year, NNT=238.
**Dose of rivaroxaban3 and apixaban4 adjusted for renal impairment,3,4 age,4 weight.4 Context:
  • While statistical significance was achieved in some endpoints, whether clinically meaningful differences exist between the agents is unknown.
  • In Canada, only dabigatran and rivaroxaban are currently approved for AF stroke prevention.
  • Appropriate patient selection important:
    • Use CHADS2, time in therapeutic INR range, and tools http://www.vhpharmsci.com/sparc/ to aid discussion.
    • NOACs contra-indicated in patients with significant renal impairment (CrCl < 30 mL/min), use lower doses if moderate renal impairment (CrCl 30-50 mL/min).5
  • Major bleeding occurs with all anticoagulants:
    • NOACs: no established reversal strategy.
    • Bleeding risk factors: (primarily from dabigatran experience): age > 80 years, impaired6 or deteriorating renal function5, < 60 kg6, and starting before INR < 2.0.6
  • Potential risk of myocardial infarction (dabigatran): Number Needed to Harm (NNH)=250-500.1,2,7


Carman Pollock December 21, 2023

This needs to be updated since apixaban is approved in Canada and reversal agents do exist for NOACS

Gillian Rosenthal January 25, 2024

Interesting.


Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Michael R Kolber MD CCFP MSc
  • Tammy Bungard BSP PharmD

1. Connelly S, Ezekowitz MD, Yusuf S, et al. N Engl J Med. 2009; 361:1139-51.

2. Connelly S, Ezekowitz MD, Yusuf S, et al. N Engl J Med. 2010; 363:1875-6.

3. Patel MR, Mahaffey KW, Garg J, et al. N Engl J Med. 2011; 365:883-91.

4. Granger CB, Alexander JH, McMurray JJV, et al. N Engl J Med. 2011; 365:981-92.

5. Health Canada Endorsed Important Safety Information on Pradax (dabigatran etexilate) March 16, 2012. Available at: http://www.boehringeringelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/120316- dhcpl.pdf. Last accessed Dec 12, 2016.

6. Harper P, Young L, Merriman E. N Engl J Med. 2012; 366:864-6.

7. Uchino K, Hernandez AV. Arch Intern Med. 2012; 172:397-402.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.